News|Articles|March 25, 2026

The First Dose Is Everything: Enhancing Adherence and Persistence with Noble SureStartRx™

Author(s)Noble
Listen
0:00 / 0:00

Key Takeaways

  • Initial self-injection is a pivotal behavioral inflection point, where anxiety and uncertainty can precipitate non-initiation or rapid discontinuation despite clinical appropriateness.
  • Remote demonstration kits provided through specialty pharmacies let patients practice technique pre-dose, improving self-efficacy and reducing friction at therapy start.
SHOW MORE

The first dose of a self-injectable therapy is a critical moment that often determines whether patients move forward with treatment or abandon it due to uncertainty. Noble’s SureStartRx™ program addresses this challenge by sending remote demonstration kits through specialty pharmacies, allowing patients to practice injections and build confidence before their first dose. Research shows that when demonstration kits are added to standard support, patients initiate therapy sooner, adhere better in the short term, and stay on treatment longer. In this discussion, Noble’s Director of Patient Engagement Services, Sean Glynn, explains how improving patient confidence at the start of therapy can protect both patient outcomes and long-term brand value.

Key Objectives

  • Understand why the first dose is a critical driver of patient adherence and persistence in self-injectable therapies.
  • Explore the impact early therapy abandonment has on patient outcomes and brand performance.
  • Learn how demonstration-based onboarding programs like SureStartRx™ can improv the overall patient experience.

DOWNLOAD Q&A

To Learn more about Noble click here:
https://www.gonoble.com/

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content